TrialAnnals of oncology : official journal of the European Society for Medical Oncology2023

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

J Remon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.